STOCK TITAN

MiniMed expects $162M charge after FDA pump clearance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MiniMed Group, Inc. (MMED) said the FDA cleared MiniMed Fit™, its first tubeless insulin pump, and now anticipates a U.S. launch in Spring 2027, ahead of the previously communicated Summer 2027 timing. The pump offers up to seven days of wear, a 300-unit insulin capacity, app control and SmartGuard™ technology.

MiniMed expects to recognize a one-time $162 million charge in fiscal Q3 2027 for the minimum payment under its research and development agreement with affiliates of Blackstone Life Sciences Advisors L.L.C. The payment obligation covers the first two years following U.S. regulatory approval and commercial launch. MiniMed expects the charge to reduce third-quarter and full-year FY2027 EBITDA and adjusted EBITDA by $162 million; related cash payments will be made over time based on product sales and other agreement terms. FY2027 adjusted EBITDA margin guidance is now approximately 11.3%, versus approximately 16% previously. MiniMed said the revision reflects only the charge, not a change in its underlying operating performance, outlook or business expectations.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.FDA clearance moves MiniMed Fit’s expected U.S. launch to Spring 2027.

Negative

  • Major point. Forward-looking: it has not happened yet and may not happen.FY2027 adjusted EBITDA margin guidance revised to approximately 11.3% from approximately 16%.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Expected U.S. launch Spring 2027 MiniMed Fit; previously communicated timing was Summer 2027
Wear duration Up to seven days MiniMed Fit patch pump
Insulin capacity 300-unit MiniMed Fit patch pump
Minimum payment obligation $162 million Expected one-time FY2027 Q3 charge; expected to reduce third-quarter and full-year FY2027 EBITDA and adjusted EBITDA
FY2027 adjusted EBITDA margin guidance Approximately 11.3% Updated from prior guidance of approximately 16%
Minimum payment period First two years Following U.S. regulatory approval and commercial launch
tubeless insulin pump medical
"MiniMed’s first tubeless insulin pump"
A tubeless insulin pump is a small, wearable device that delivers programmed doses of insulin directly through a patch on the skin, without the external tubing found on traditional pumps. For investors, it matters because these devices can increase patient convenience and adherence, potentially expanding market size, driving recurring sales of disposable pods and supplies, and influencing reimbursement and regulatory risk in the diabetes-care market—similar to how cordless tools changed demand compared with corded models.
SmartGuard™ technology technical
"app control and SmartGuard™ technology"
adjusted EBITDA margin financial
"FY2027 adjusted EBITDA margin guidance"
Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.
non-GAAP financial measure financial
"Adjusted EBITDA margin, which is a non-GAAP financial measure"
A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.
minimum payment obligation financial
"minimum payment obligation under the agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will MMED launch MiniMed Fit in the U.S.?

MiniMed now anticipates a U.S. launch in Spring 2027, ahead of the previously communicated Summer 2027 timing. The pump offers up to seven days of wear, a 300-unit insulin capacity, app control and SmartGuard™ technology.

What is MMED’s updated FY2027 adjusted EBITDA margin guidance?

MiniMed updated its FY2027 adjusted EBITDA margin guidance to approximately 11.3% from approximately 16%. It said the revision solely reflects the $162 million MiniMed Fit charge and not a change in its underlying operating performance, operating outlook or business expectations.

How are the cash payments for MMED’s MiniMed Fit obligation made?

The associated cash payments will be made over time based on product sales and other terms of the research and development agreement with affiliates of Blackstone Life Sciences Advisors L.L.C.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0002062583 0002062583 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

 

MiniMed Group, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware 001-43183 33-3985981
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

18000 Devonshire St.

Northridge, CA 91325

(Address of principal executive offices) (Zip Code)

 

(763) 514-4000

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of exchange on which registered
Common Stock, $0.01 par value   MMED   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On November 16, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology. FDA clearance was received several months ahead of expectations and is expected to accelerate U.S. commercialization of this key product, which is now anticipated to launch in Spring 2027 in advance of the previously communicated timing of Summer 2027.

 

Given the FDA clearance of MiniMed Fit, MiniMed is expected to recognize a one-time charge in the third quarter of fiscal year 2027 related to the previously disclosed minimum payment of $162 million for the first two years following regulatory approval in the United States and commercial launch of the MiniMed Fit patch pump under its research and development agreement with affiliates of Blackstone Life Sciences Advisors L.L.C., which became an obligation of MiniMed in connection with its separation from Medtronic plc. Consistent with the accounting treatment applied following FDA clearance of MiniMed Flex™ in the fourth quarter of fiscal year 2026, MiniMed does not intend to exclude this charge from adjusted EBITDA. Accordingly, third quarter and full fiscal year 2027 EBITDA and adjusted EBITDA are expected to be reduced by $162 million. The charge will reflect the income statement recognition of the minimum payment obligation under the agreement, while the associated cash payments will be made over time based on product sales and other terms of the agreement.

 

Because the charge was not contemplated in MiniMed's previously issued fiscal year 2027 adjusted EBITDA margin guidance, MiniMed is updating its fiscal year 2027 adjusted EBITDA margin guidance to approximately 11.3%, compared with its prior guidance of approximately 16%. The updated guidance solely reflects the $162 million charge associated with MiniMed Fit™ and does not reflect any change in MiniMed’s underlying operating performance, operating outlook, or expectations for the business.

 

Non-GAAP Financial Measures

 

MiniMed calculates forward-looking Adjusted EBITDA margin, which is a non-GAAP financial measure, based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. MiniMed does not provide a reconciliation of forward-looking non-GAAP measures to the comparable GAAP measure because certain items cannot be reasonably predicted without unreasonable effort. Such items could have a substantial impact on GAAP measures of financial performance.

 

Forward-Looking Statements Disclaimer

 

This filing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to MiniMed’s anticipated financial results for the third quarter of fiscal year 2027 and for fiscal year 2027. These risks and uncertainties are described in MiniMed’s filings with the U.S. Securities and Exchange Commission. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. MiniMed does not undertake to update its forward-looking statements or any of the information contained in this filing, including to reflect future events or circumstances.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MiniMed Group, Inc.
     
Date: November 16, 2026 By: /s/ Chad Spooner
  Name: Chad Spooner
  Title: Executive Vice President and Chief Financial Officer (Principal Financial Officer)

 

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading